Policies & RegulationsPharmacyHospitalsPharma & DistributionDrug ApprovalsIP IssuesDomestic NDD
  news bulletin  
Chong Kun Dang and Hanmi won Atacand patent case
by Eui Kyoung Yoon (ekyeun@dreamdrug.com)
Published : Mar 7, 2013 04:45:27
Chong Kung Dang (CKD) and Hanmi won the Atacand patent case against Teva as Korea Intellectual Property Tribunal sided with CKD and Hanmi on February 27.

Teva had insisted its manufacturing method of candesartan cilexetil should have been valid although the patent on the substance expired in 2011.

Teva also filed its patent infringement case for its pharmaceutical active ingredient, candesartan cilexetil, against CKD and Kyoundong previously, but the court sided with Korean drugmakers.

An official of a Korean drug maker said, “Teva may be able to win its patent cases in other countries. But Korea is different. Teva may struggle in Korea with its patent protection strategy for first generic drugs.”

CKD’s generic version of Atacand racked up 10 billion won last year despite of the pending patent cases.
Reply 0
Name Password
Popular News
Champix to be covered, starting Feb 2015
First generic version of Omacor approved
OTC drugs will be available at some resorts
Novartis Korea and KPWA agreed on margin increase
MSD’s new COX-2 inhibitor Arcoxia approved
All materials contained on this site are protected by Korean copyright law and may not be reproduced, distributed, transmitted,
displayed, published or broadcast without the prior consent of dailypharm.com